

Supplemental Table 3: Treatment modality and resultant renal function

Patient	Treatment at first presentation	Dialysis (duration if recovery)	ERF	Relapse	Renal Transplant	Subsequent treatment	Duration of follow up (months)	eGFR (mL/min/1.73m ²) at most recent follow up
2	FFP, PEX	Yes (5 weeks)	No	Yes	n/a	PEX at relapse	163	>60 [†]
4	FFP, PEX, IVIG	Yes	Yes	No	Yes aHUS recurrence	ECU post-transplant	75	47.6*
5	PEX	Yes	Yes	No	Yes Graft failure (AMR)		151	ERF
6	PEX	Yes	Yes	No	No. Ineligible		130	ERF
10	PEX, CS	No	No	Multiple	n/a	Regular PEX, withdrawn 2012	117	>60*
12	FFP, PEX, IVIG	Yes	Yes	No	Yes		98	>60*
14	FFP, ECU	No	No	No	n/a		7	>60*
15	ECU	Yes (5 days)	No	No	n/a		11	>60*
16	PEX	Yes (3 days)	No	Yes	n/a	ECU at relapse	81	>53*
17	PEX	No	No	No	n/a		108	>60*
18	FFP, PEX	No	No	Yes	n/a	PEX at relapse	123	>60*
19	SUP	Yes	Yes	No	Yes		64	48.4*
20	ECU	No	No	No	n/a		62	>60*
21	FFP, PEX	Yes (6 days)	No	Yes	n/a	PEX, RTX at relapse	9	>60 [†]
22	SUP	Yes	Yes	No	Yes		84	>60*
23	PEX	Yes (5 days)	No	No	n/a		12	>60*
24	ECU	Yes (5 weeks)	No	No	n/a		22	52.3*

eGFR: by Schwartz formula for patients <18 years at last follow up (*) and by abbreviated MDRD equation for patients >18 at last follow up (†)

Abbreviations: AMR, antibody mediated rejection; CS, corticosteroids; ECU, eculizumab; eGFR: estimated glomerular filtration rate; ERF, established renal failure; FFP, fresh frozen plasma; IVIG, intravenous immunoglobulin; MMF, mycophenolate mofetil; n/a, not applicable; PEX, plasma exchange; RTX, rituximab; SUP, supportive management.